StockData
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31

ACADIA PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$19.80+0.68 (+3.56%)

Close on Oct 19, 2026

Market cap
$3.42B
P/E (TTM)
9.0
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 4, 2026During market hours–$0.18–
Q1 FY2026
Ended Mar 31, 2026
May 6, 2026During market hours$268.00M$0.02–
Q4 FY2025
Ended Dec 31, 2025
Feb 25, 2026During market hours$284.00M$1.60–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025During market hours$278.60M$0.42–
Q2 FY2025
Ended Jun 30, 2025
Aug 6, 2025During market hours$264.60M$0.16–
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025During market hours$244.30M$0.11–
Q4 FY2024
Ended Dec 31, 2024
Feb 26, 2025During market hours$259.60M$0.86–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024During market hours$250.40M$0.20–
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Feb 27, 2024During market hours–––

Company guidance

Outlook given with results on Aug 4, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
SG&A expenseGAAPFull Year 2026$660.00M to $700.00MRaised
R&D expenseGAAPFull Year 2026$355.00M to $380.00MLowered
Total revenuesGAAPFull Year 2026$1.24B to $1.30BRaised
NUPLAZID net product salesGAAPFull Year 2026$760.00M to $790.00MLowered
DAYBUE (including all forms of trofinetide) global net product salesGAAPFull Year 2026$480.00M to $510.00MLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Acadia Pharmaceuticals filed with the SEC